ArticleOncology letters2017
Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Machine Learning-Assisted FTIR Analysis of Circulating Extracellular Vesicles for Cancer Liquid Biopsy.Journal of personalized medicine · 2022Article
- Circular RNA TADA2A promotes proliferation and migration via modulating of miR‑638/KIAA0101 signal in non‑small cell lung cancer.Oncology reports · 2021Article
- MicroRNA-638 inhibits the progression of breast cancer through targeting HOXA9 and suppressing Wnt/β-cadherin pathway.World journal of surgical oncology · 2021Article
- Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1.OncoTargets and therapy · 2020Article
- Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer.Journal of hematology & oncology · 2019Review
- Expression of miR-664-3p in Osteosarcoma and Its Effects on the Proliferation and Apoptosis of Osteosarcoma Cells.Iranian journal of public health · 2019Article
- Expression of miR-204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells.Oncology letters · 2018Article
- The microRNA expression signature of CD4+ T cells in the transition of brucellosis into chronicity.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs/miRs) have been identified as important post-transcriptional regulators in healthy liver physiology and liver diseases. However, the clinical significance of miR-638 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to investigate the status of miR-638 expression in HCC and to determine its clinical significance. The expression of miR-638 was evaluated in 60 HCC tissues samples and HCC SMMC-7721, HepG2 and Hep3B cell lines using reverse transcription-quantitative polymerase chain reaction. The association between the expression of miR-638 and the clinicopathological characteristics of patients with HCC was analyzed. The proportion of HCC patients with low miR-638 expression was identified as 68.3% (41/60). Furthermore, significantly lower miR-638 expression was identified in HCC tissue samples compared with the healthy control group (P=0.031). miR-638 expression was significantly lower in SMMC-7721 (P=0.021), HepG2 (P=0.005) and Hep3B (P=0.003) cells compared with the healthy human hepatic HL-7702 cell line. In addition, miR-638 expression was correlated with α-fetoprotein levels (P=0.042) and portal vein invasion (P=0.025). The area under curve was identified as 0.71 (95% confidence interval=0.63-0.79; P=0.001). The cut-off value for miR-638 was the median 2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.